

101617303

Practitioner's Docket No.: PH-7193 Div

Cofc

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary K. VanAtten
Type or print name

Mary VanAtten
Signature

February 16, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. PATENT: 6,949,546

PATENTEE: Soo S. Ko, James R. Pruitt, Dean A. Wacker, and Douglas G. Batt

ISSUED: Sep. 27, 2005

ASSIGNEE: Bristol Myers Squibb Pharma Company

TITLE: N-UREIDOHETEROCYCLOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Date: February 16, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-140
Attn: Decision and Certificate Branch of Patent Issue Division

Sir:

Certificate
FEB 24 2006
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
PURSUANT TO 37 C.F.R §1.322 AND 37 C.F.R §1.323

The patentees through their agent hereby respectfully request that a certificate of correction be issued to correct printing errors in accordance with the attached Certificate of Correction Form 1050, submitted in duplicate, herewith.

Pursuant to 37 C.F.R §1.322, patentees request that a certificate of correction enclosed herewith be issued for mistakes by the Patent and Trademark Office. Also pursuant to 37 C.F.R §1.323, patentees request that a certificate of correction enclosed herewith be issued for mistakes by patentees. The mistakes made by the Patent and Trademark Office are tabulated in Table 1 and those made by patentees are in List 1.

Support for the requested corrections can be found in the application. The requested corrections for mistakes by patentees are clerical or typographical in nature and do not involve such changes in the patent as would constitute new matter or would require re-examination.

02/22/2006 SFELEKE1 00000098 193880 6949546

01 FC:1811 100.00 DA

Table 1 : Mistakes made by the Patent and Trademark Office

– U.S. Patent 6,949,546

Corrections requested in the patent:	Errors shown correctly in Applicant's Amendment of 1/3/2005
In column 258, line 28, delete the "at each occurrence1 is" and insert -- at each occurrence is --	Amendment, page 2
In column 260, line 58, delete the "R ^{10a} ," and insert -- R ^{10e} , --	Amendment, page 12
In column 263, lines 18-19, delete the "and (CH ₂) _r phenyl" and insert -- and (CH ₂) _r phenyl --	Amendment, page 19
In column 264, line 53, delete the "OH ₂ -OC ₁₋₅ alkyl," and insert -- CH ₂ -OC ₁₋₅ alkyl, --	Amendment, page 23
In column 266, line 59, delete the "13 CH ₂ C≡CH;" and insert -- CH ₂ C≡CH; --	Amendment, page 29

List 2. Mistakes made by Patentees

The requested corrections are minor in character and do not constitute new matter. The changes would not require reexamination.

In column 260, lines 26-27, delete the "from C₁₋₆ alkyl, C₃₋₆ cycloalkyl;" and insert -- from C₁₋₆ alkyl, and C₃₋₆ cycloalkyl; --. The minor typographical mistake can be found in the Amendment, page 11.

In column 262, lines 62-63, delete the "from C₁₋₆ alkyl, C₃₋₆ cycloalkyl;" and insert -- from C₁₋₆ alkyl, and C₃₋₆ cycloalkyl; --. The minor typographical mistake can be found in the Amendment, page 18.

In column 264, line 4, delete the "tetrahycrofuranyl" and insert -- tetrahydrofuranyl --. The minor typographical mistake can be found in the Amendment, page 22.

In column 265, line 7, delete the "from cyclpropyl" and insert -- from cyclopropyl --. The minor typographical mistake can be found in the Amendment, page 24.


On account of the corrections Applicants request pursuant to 37 CFR 1.323, the Commissioner is authorized to charge the \$100 fee under 37 CFR 1.20(a) to Deposit

Account No. 19-3880. Additionally, the Commissioner is authorized to charge any additional fee that may be required for this request to the aforementioned Deposit Account. The USPTO is requested to kindly contact the undersigned if deemed appropriate to expedite this request.

Please send the Certificate to:


Mary VanAtten
Bristol-Myers Squibb Pharma Company
c/o Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Bristol-Myers Squibb Pharma Company
(Assignee)


(Person authorized to sign on behalf of assignee)
Mary Van Atten

Assignments on the above patent were recorded on **January 15, 2002 and February 11, 2002**, and can be found on Reel/Frame Nos. 012490/0053 (2 pages) and 012607/0038 (17 pages) to Assignee, DuPont Pharmaceutical Company, now d.b.a. Bristol-Myers Squibb Pharma Company.

Respectfully submitted,


Mary VanAtten
Agent for Patentees
Registration No. 39,408
Telephone: 609-252-4379

Attachment (Form 1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,949,546

Page 1 of 1

DATED : Sep. 27, 2005

INVENTOR(S) : Soo S. Ko, James R. Pruitt, and Dean A. Wacker, and Douglas G. Batt

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 258, line 28, delete the "at each occurrence1 is" and insert -- at each occurrence is --;
at column 260, line 58, delete the " R^{10a} ," and insert -- R^{10e} , --;
at column 260, lines 26-27, delete the "from C_{1-6} alkyl, C_{3-6} cycloalkyl;" and insert -- from C_{1-6} alkyl, and C_{3-6} cycloalkyl; --;
at column 262, lines 62-63, delete the "from C_{1-6} alkyl, C_{3-6} cycloalkyl;" and insert -- from C_{1-6} alkyl, and C_{3-6} cycloalkyl; --.
at column 263, lines 18-19, delete the "and $(CH_2)_r$ phenyl" and insert -- and $(CH_2)_r$ phenyl --;
at column 264, line 4, delete the "tetrahycrofuranyl" and insert -- tetrahydrofuranyl --;
at column 264, line 53, delete the " OH_2-OC_{1-5} alkyl," and insert -- CH_2-OC_{1-5} alkyl, --;
at column 265, line 7, delete the "from cyclopropyl" and insert -- from cyclopropyl;
at column 266, line 59, delete the " $13 CH_2C\equiv CH$;" and insert -- $CH_2C\equiv CH$; --.

Certificate of Correction (PTO Form 1050) (reproduced)

PATENT NO.: 6,949,546

MAILING ADDRESS OF SENDER:

Mary VanAtten

Bristol-Myers Squibb Pharma Company

c/o Patent Department

P.O. Box 4000

Princeton, NJ 08543-4000

FEB 1 2006